Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

European OTC Market In Brief

This article was originally published in The Tan Sheet

Executive Summary

Boomtown Kazakhstan: Ukraine and Kazakhstan have emerged as top OTC market opportunities in Central and Eastern Europe, according to consultant Duncan McLaughlin of CEE Business Development. "Don't forget Kazakhstan. It's a booming economy - get your suitcase, get your briefcase and go out there and do the deals," McLaughlin said April 11 at Nicholas Hall's Insight 19th Annual European OTC Conference in Athens. Non-pharmacy access to OTC drugs is not consistent across countries in the region, but most are liberalizing their regulations, he added. In five to 10 years, "I think we will see a lot more non-pharmacy sales in CEE than what we are seeing in mainstream Western Europe," he said. Like other markets, drug firms have better chances for success in CEE with "products and brands with really tangible and communicable differences. We all know that - we don't always do that," McLaughlin said...

You may also be interested in...



People In Brief

Perrigo promotes in pricing, planning

In Brief

Combe sells most of its OTC brands

Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC

Topics

UsernamePublicRestriction

Register

PS101662

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel